IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology
IMAC Holdings Inc. (Nasdaq: BACK) has launched a new subsidiary, Ignite Proteomics , introducing a groundbreaking precision oncology assay for breast cancer treatment using Reverse Phase Protein Array (RPPA) technology. This follows IMAC's acquisition of key assets from Theralink Technologies, Inc. A landmark clinical case study published in npj Precision Oncology demonstrates the power of RPPA in precision oncology.
The case study highlights a 57-year-old woman with metastatic triple-negative breast cancer who achieved a complete response to therapy guided by Ignite's RPPA-based analysis. The assay identified HER2 expression and activation, missed by conventional methods, leading to successful treatment with trastuzumab deruxtecan (T-DXd).
Ignite Proteomics offers the only commercially available and clinically validated assay measuring both expression and activated protein drug target levels in breast tumors, potentially revolutionizing targeted cancer therapies.
IMAC Holdings Inc. (Nasdaq: BACK) ha lanciato una nuova sussidiaria, Ignite Proteomics, introducendo un innovativo test di oncologia di precisione per il trattamento del cancro al seno utilizzando la tecnologia Reverse Phase Protein Array (RPPA). Questo segue l'acquisizione da parte di IMAC di beni chiave da Theralink Technologies, Inc. Uno studio clinico innovativo pubblicato su npj Precision Oncology dimostra l'efficacia della RPPA nell'oncologia di precisione.
Lo studio di caso evidenzia una donna di 57 anni con cancro al seno triplo negativo metastatico che ha ottenuto una risposta completa alla terapia guidata dall'analisi basata su RPPA di Ignite. Il test ha identificato l'espressione e l'attivazione di HER2, non rilevata dai metodi convenzionali, portando a un trattamento di successo con trastuzumab deruxtecan (T-DXd).
Ignite Proteomics offre l'unico test commercialmente disponibile e clinicamente convalidato che misura sia i livelli di espressione che quelli dei target proteici attivati nei tumori al seno, potenzialmente rivoluzionando le terapie oncologiche mirate.
IMAC Holdings Inc. (Nasdaq: BACK) ha lanzado una nueva subsidiaria, Ignite Proteomics, presentando un innovador ensayo de oncología de precisión para el tratamiento del cáncer de mama utilizando la tecnología Reverse Phase Protein Array (RPPA). Esto sigue a la adquisición por parte de IMAC de activos clave de Theralink Technologies, Inc. Un estudio de caso clínico publicado en npj Precision Oncology demuestra el poder de la RPPA en la oncología de precisión.
El estudio de caso destaca a una mujer de 57 años con cáncer de mama triple negativo metastásico que logró una respuesta completa a la terapia guiada por el análisis basado en RPPA de Ignite. El ensayo identificó la expresión y activación de HER2, que fue pasada por alto por métodos convencionales, llevando a un tratamiento exitoso con trastuzumab deruxtecan (T-DXd).
Ignite Proteomics ofrece el único ensayo comercialmente disponible y clínicamente validado que mide tanto la expresión como los niveles de proteínas activadas diana en tumores de mama, lo que podría revolucionar las terapias contra el cáncer dirigidas.
IMAC Holdings Inc. (Nasdaq: BACK)는 새로운 자회사 Ignite Proteomics를 출시하여 역상 단백질 배열(RPPA) 기술을 활용한 유방암 치료를 위한 혁신적인 정밀 온콜로지 시험을 소개했습니다. 이는 IMAC이 Theralink Technologies, Inc.로부터 주요 자산을 인수한 이후의 일입니다. npj Precision Oncology에 발표된 기념비적인 임상 사례 연구는 정밀 온콜로지에서 RPPA의 힘을 보여줍니다.
이 사례 연구는 전이성 삼중 음성 유방암 환자인 57세 여성의 치료를 Ignite의 RPPA 기반 분석에 따라 이끌어 완전 반응을 이끌어냈습니다. 이 시험은 기존 방법에서 놓친 HER2의 발현 및 활성화를 식별하여 trastuzumab deruxtecan (T-DXd)으로 성공적인 치료에 이르게 하였습니다.
Ignite Proteomics는 유방 종양에서 발현 및 활성화된 단백질 약물 표적 수준을 모두 측정하는 유일한 상업적으로 이용 가능한 임상 검증된 시험을 제공하여 표적 암 치료법을 혁신할 수 있는 잠재력을 가지고 있습니다.
IMAC Holdings Inc. (Nasdaq: BACK) a lancé une nouvelle filiale, Ignite Proteomics, présentant un essai révolutionnaire d'oncologie de précision pour le traitement du cancer du sein utilisant la technologie Reverse Phase Protein Array (RPPA). Cela fait suite à l'acquisition par IMAC d'actifs clés de Theralink Technologies, Inc. Une étude de cas clinique publiée dans npj Precision Oncology démontre la puissance de la RPPA dans l'oncologie de précision.
L'étude de cas met en avant une femme de 57 ans atteinte d'un cancer du sein triple négatif métastatique qui a obtenu une réponse complète à la thérapie guidée par l'analyse basée sur RPPA d'Ignite. L'essai a identifié l'expression et l'activation de HER2, passés inaperçus par les méthodes conventionnelles, ce qui a conduit à un traitement réussi avec le trastuzumab deruxtecan (T-DXd).
Ignite Proteomics propose le seul essai disponible commercialement et validé cliniquement mesurant à la fois les niveaux d'expression et de protéines cibles activées dans les tumeurs du sein, ce qui pourrait révolutionner les thérapies ciblées contre le cancer.
IMAC Holdings Inc. (Nasdaq: BACK) hat eine neue Tochtergesellschaft, Ignite Proteomics, gegründet und ein bahnbrechendes Präzisionsonkologie-Assay zur Behandlung von Brustkrebs vorgestellt, das die Reverse Phase Protein Array (RPPA)-Technologie nutzt. Dies folgt auf den Erwerb wichtiger Vermögenswerte von Theralink Technologies, Inc. Eine wegweisende klinische Fallstudie, veröffentlicht in npj Precision Oncology, zeigt die Kraft von RPPA in der Präzisionsonkologie.
Die Fallstudie hebt eine 57-jährige Frau mit metastasiertem dreifach negativem Brustkrebs hervor, die auf eine Therapie reagierte, die auf der Analyse von Ignites RPPA basierte, und eine komplette Remission erreichte. Das Assay identifizierte HER2-Expression und -Aktivierung, die durch konventionelle Methoden übersehen wurde, was zu einer erfolgreichen Behandlung mit Trastuzumab Deruxtecan (T-DXd) führte.
Ignite Proteomics bietet das einzige kommerziell verfügbare und klinisch validierte Assay zur Messung sowohl der Expression als auch der aktivierten Protein-Darreichungspegel in Brusttumoren, was potenziell die zielgerichteten Krebstherapien revolutionieren könnte.
- Launch of a new precision oncology assay for breast cancer treatment using RPPA technology
- Successful clinical case study demonstrating complete response to therapy guided by RPPA-based analysis
- Only commercially available and clinically validated assay measuring both expression and activated protein drug target levels in breast tumors
- Potential to revolutionize targeted cancer therapies and improve patient outcomes
- None.
This groundbreaking case study demonstrates the potential of Reverse Phase Protein Array (RPPA) technology in precision oncology. The ability to detect HER2 activation missed by conventional methods is a significant advancement. It highlights the limitations of current IHC and NGS testing, which may overlook important protein activations. This technology could revolutionize treatment decisions, especially for triple-negative breast cancer patients who typically have targeted therapy options.
The complete response achieved in this case is particularly noteworthy. It suggests that RPPA could identify more patients who might benefit from HER2-targeted therapies, potentially expanding the use of drugs like trastuzumab deruxtecan. However, larger studies are needed to confirm these findings and establish the predictive value of RPPA in various cancer types.
The launch of Ignite Proteomics and its novel RPPA assay positions IMAC Holdings (NASDAQ: BACK) at the forefront of the precision oncology market. This market is projected to reach
However, investors should consider:
- The cost and scalability of RPPA technology
- Potential competition from established diagnostic companies
- The need for further clinical validation and regulatory approvals
The introduction of RPPA technology by Ignite Proteomics could significantly impact cancer treatment protocols and healthcare policies. If further validated, this approach might necessitate updates to clinical guidelines for breast cancer diagnosis and treatment. The potential to identify more patients who could benefit from targeted therapies could lead to:
- Improved patient outcomes
- More cost-effective treatment strategies
- Reduced use of ineffective therapies
However, the healthcare system will need to address challenges such as:
- Integrating RPPA testing into standard diagnostic workflows
- Ensuring equitable access to this advanced technology
- Developing appropriate reimbursement models
Nashville, TN, Sept. 19, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC Holdings” or the “Company”), a leader in innovative healthcare solutions, proudly announces the launch of an entirely new precision oncology assay for breast cancer treatment decision making utilizing the Reverse Phase Protein Array (RPPA) technology through its newly established subsidiary, Ignite Proteomics LLC (“Ignite Proteomics”). This launch follows IMAC Holdings’ strategic acquisition of key assets from Theralink Technologies, Inc., and is underscored by a landmark clinical case study “Proteomics based selection achieves complete response to HER2 therapy in HER2 IHC 0 breast cancer”, demonstrating the power of RPPA technology in precision oncology published in npj Precision Oncology, an international, peer-reviewed journal focused on precision oncology.
Revolutionizing Cancer Care with Precision Oncology
Ignite Proteomics introduces the only commercialy available and clinically validated assay that can measure both the expression and activated protein drug target levels in breast tumors, a superior way to measure the potential effectiveness of targeted cancer therapies. The clinical utility of the Ignite proteomic assay is highlighted by this recent case study involving a 57-year-old woman with metastatic triple-negative breast cancer (TNBC) who exhibited an exceptional response to treatment guided by Ignite’s RPPA-based analysis.
Case Study Highlights: A Breakthrough in Precision Medicine
Despite previous extensive treatments including chemotherapy and targeted therapies, the patient experienced disease progression across multiple sites (brain, mediastinal lymph nodes, lungs, chest wall, liver, and skin). A clinical trial at the Inova Schar Cancer Institute (ISCI) allowed for a comparative analysis using both current next-generation sequencing (NGS) assays and Ignite’s novel assay on the same biopsy. After Ignite Proteomics RPPA assay identifed the expression and activation of an important protein called HER2, which was missed by both the NGS analysis and current approaches to measure HER2 the patient was treated with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) , which relies on HER2 expression and activation to work. After 9 cycles no measurable disease was observed, representing a complete response to therapy.
“The RPPA technology and our novel proteomics assay represent a transformative advancement in the management of breast cancer, providing critical insights that enable us to tailor treatments with greater precision and effectiveness,” said Faith Zaslavsky, CEO of IMAC Holdings and Ignite Proteomics. “The remarkable response observed in this case study underscores the role our assay can play in significantly impacting patient outcomes.”
About IMAC Holdings, Inc.
IMAC Holdings, Inc. is dedicated to advancing healthcare through innovative solutions that improve patient outcomes. With a focus on strategic acquisitions and pioneering technologies, IMAC Holdings is at the forefront of precision medicine.
About Ignite Proteomics
Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., specializes in advanced RPPA technology for cancer diagnostics. As the only provider of a CLIA-accredited RPPA assay for breast cancer, Ignite Proteomics is setting new benchmarks in protein-based testing and personalized oncology care.
For additional information, please contact:
Investors@imacholdings.com
FAQ
What is the new precision oncology assay launched by IMAC Holdings (BACK) for breast cancer treatment?
How did the RPPA technology by Ignite Proteomics (BACK) help in the case study of a 57-year-old woman with metastatic triple-negative breast cancer?
What makes the Ignite Proteomics (BACK) assay unique in the field of breast cancer diagnostics?
Where was the clinical case study demonstrating the effectiveness of IMAC Holdings' (BACK) RPPA technology published?
